Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II
Authors:
- 23 February 2013
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 288 (2) , 393-400
Abstract
We investigated the effects of the anti-epilepsy drug valproic acid (VPA) alone and in combination in treating cervical cancer.Keywords
This publication has 21 references indexed in Scilit:
- Notch1-Mediated Tumor Suppression in Cervical Cancer with the Involvement of SST Signaling and Its Application in Enhanced SSTR-Targeted TherapeuticsThe Oncologist, 2012
- PTEN Tumor Suppressor Network in PI3K-Akt Pathway ControlGenes & Cancer, 2010
- Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinomaBritish Journal of Cancer, 2010
- Posttranslational regulation of BCL2 levels in cerebellar granule cells: A mechanism of neuronal survivalDevelopmental Neurobiology, 2009
- Inhibition of Growth in Medullary Thyroid Cancer Cells with Histone Deacetylase Inhibitors and Lithium ChlorideJournal of Surgical Research, 2008
- Notch tumor suppressor functionOncogene, 2008
- Valproic Acid Induces Notch1 Signaling in Small Cell Lung Cancer CellsJournal of Surgical Research, 2008
- Epithelial-Mesenchymal Transition Events during Human Embryonic Stem Cell DifferentiationCancer Research, 2007
- Snail-Induced Down-Regulation of ΔNp63α Acquires Invasive Phenotype of Human Squamous Cell CarcinomaCancer Research, 2007
- TGFβ1 induces epithelial–mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary cultureInternational Journal of Experimental Pathology, 2006